基因疗法新型冠状病毒感染COVID-19 vaccine (Mass General Brigham)疫苗抗体细胞疗法并购
Gene therapy encompasses an advanced medical treatment for numerous chronic and genetic disorders in humans. This is achieved by replacing a defective gene cell with a healthy gene cell. Through gene therapy,
chronic and genetic disorders
that do not have developed cures can be prevented. Developers of gene therapy are quickly expanding their businesses through acquisitions and mergers. New product launch deals are being signed as a strategy to strengthen product trails and augment in-house proficiency.
Onslaught of the
pandemic has accelerated the application of gene therapy. Technology for gene and cell therapy is anticipated to be excessively applied for developing vaccines. In January 2019, Mass General Brigham developed vaccine candidates which stimulated convincing immune responses from animal models in treatment of the novel coronavirus. The vaccine candidate named AAVCOVID, was developed through gene-therapy technology and received a grant of USD 2.1 Million for further research. Similarly, researchers from the University of Pennsylvania have started using adeno-associated viral vectors to transmit lab-made antibodies into the body.